Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

NCT01568866 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01568866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01568866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
June 20, 2012
Completion date
February 5, 2018
Enrollment
929 (actual)
Sites
241

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma